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Abstract
We aimed to evaluate the association of albuminuria and estimated glomerular filtration rate (eGFR) at baseline and changes
in these parameters with left ventricular mass index (LVMI) at 7 years in adults with hypertension from communities in
Pakistan. A nested cohort of 539 hypertensives aged 40 years and older from a community-living population in Karachi,
Pakistan, followed up for 7 years in the Control of Blood Pressure and Risk Attenuation trial. Urine spot albumin-tocreatinine ratio (UACR) and serum creatinine-based eGFR were assessed at baseline and 7 years, and echocardiography
at 7 years. Mean age of participants was 50.9  9.1 (standard deviation) years; 63% were female. Mean eGFR was
91.0  15.9 (standard deviation) mL/min/1.73 m2 and median (interquartile range) UACR 6.2 (3.9, 11.3) mg/g. In multivariate analysis, although baseline eGFR was marginally associated with LVMI, a strong association was found between higher
LVMI with greater rate of decline in eGFR (b ¼ 1.05; 95% confidence interval [CI]: [1.94, 0.17]). Higher baseline
UACR was significantly associated with higher follow-up LVMI (b ¼ 2.26; 95% CI: [0.87, 3.65]), as was rate of UACR increase of 1.07 mg/g/y versus of <0.14 mg/g/y. (b ¼ 4.19; 95% CI: [0.75, 7.63]). Associations with developing left ventricular hypertrophy were found for reduced baseline eGFR, higher baseline UACR, and greater rate of UACR increase,
but not for rate of eGFR decline. Comparable results were observed for the outcomes of posterior wall thickness and septal
wall thickness. Higher baseline albuminuria, lower baseline eGFR, and their longitudinal worsening were significantly associated with higher LVMI or the development of left ventricular hypertrophy among individuals with hypertension in Pakistan.
J Am Soc Hypertens 2017;11(12):811–822. Ó 2017 The Authors. Published by Elsevier Inc. on behalf of American Society
of Hypertension. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Creatinine; glomerular filtration rate; left ventricular hypertrophy.
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Higher left ventricular mass index (LVMI) or left ventricular hypertrophy (LVH) is indicative of hypertensive
target organ damage and is predictive of future cardiovascular morbidity and mortality.1,2 Kidney dysfunction, manifested as reduced estimated glomerular filtration rate
(eGFR)3 or as albuminuria,4 is also a marker of hypertensive target organ damage and is independently associated
with mortality and increased risk of cardiovascular
event.4–6 In addition, LVH and kidney dysfunction often
coexist, as has been shown in cross-sectional studies.7,8

1933-1711/Ó 2017 The Authors. Published by Elsevier Inc. on behalf of American Society of Hypertension. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Longitudinal data are limited and suggest a bidirectional
relationship between kidney dysfunction and LV mass.
Higher baseline LVMI has been associated with lower
eGFR and LVH with rapid decline in eGFR.9,10 More
recently, studies in individuals without advanced kidney
disease showed that lower baseline eGFR and rapid decline
in eGFR predicted higher future LVMI.11 Furthermore,
baseline albuminuria and change in albuminuria have
been shown to be predictive of LVH regression12,13 and
greater left ventricular mass (LVM).14 However, the combined impact of dynamic changes in both eGFR and albuminuria on LVM has not been reported.
The South Asian population is known to be at high risk
for cardiovascular disease (CVD) and kidney disease, and
related premature mortality.15,16 However, studies in South
Asians evaluating the association between kidney dysfunction and LVM are scarce, with existing reports limited
largely to whites or African-American populations.17
We conducted a prospective study in a nested cohort of
539 individuals with hypertension from the general population in Karachi, Pakistan, with an average follow-up of
7 years, as part of the Control of Blood Pressure and
Risk Attenuation (COBRA) trial.18 We assessed the association of baseline eGFR, change in eGFR, and baseline albuminuria and change in albuminuria, and their combined
effect on LV mass after 7 years of follow-up. We hypothesized that in hypertensive adults from the general population in Karachi, reduced eGFR, and/or increased
albuminuria at baseline or their worsening during followup, is each independently associated with higher LVM, independent of other risk factors.

Methods
Study Population
We conducted a post hoc analysis of data from the COBRA trial, a cluster randomized controlled trial of hypertensive individuals in communities of Karachi, Pakistan,
between 2004 and 2014.18 Details regarding recruitment
procedures have been published elsewhere.18 Briefly, 12
geographic census-based clusters were selected using a
multistage random sampling technique. In order to examine
the intervention effect, a 2  2 factorial design was used to
randomly assign three clusters to four study groups: home
health education, general practitioner training, home health
education and general practitioner combined, and no intervention. Participants were chosen by door-to-door visits
within each of the 12 clusters. Eligible participants were
residents of selected clusters, aged 40 year and older with
known hypertension or consistently elevated blood pressure
(BP) on 2 of 3 visits (mean of 2 of 3 measurements of systolic BP 140 mm Hg or diastolic BP 90 mm Hg). Exclusion criteria were pregnancy or severe mental or physical
disability. The Aga Khan University Ethics Review

Committee granted ethical approval, and informed consent
was obtained from each participant.

Screening and Recruitment
Trained research staff visited all households in each of
the 12 clusters and screened all eligible adults aged 40 years
or older for hypertension after obtaining informed consent.
All recruited participants underwent routine medical
history taking, physical examination, and laboratory assessment. Baseline measurements were obtained in 2004–2005.
A standardized questionnaire was administered to collect
information on age, gender, education, smoking, selfreported antihypertensive use, history of diabetes, and history of heart disease. Body mass index (weight [kg]/height2
[meter]2) was calculated, and BP was measured three times
in the sitting position. Mean values of the last two BP readings taken were used for analysis.
As previously described, serum creatinine measurements
were calibrated at the Cleveland Clinic reference laboratory
where serum creatinine levels were measured using the
Roche enzymatic creatinine assay (in duplicate) which is
traceable to the National Institute of Standards and Technology creatinine reference measurement.19 Glomerular
filtration rate was estimated at baseline and end of study using the CKD-EPI (CKD Epidemiology Collaboration)
Pakistan (CKD-EPI_PK) equation, a modified version of
CKD-EPI creatinine-based equation with a correction factor (0.686  CKD-EPI1.059) for South Asians. eGFR
based on this equation denoted eGFR CKD-EPI(PK).
This equation has been validated in the local population
and performs better than the original CKD-EPI equation.19
Urine albumin excretion was measured by nephelometry
using the Array Systems method on a Beckman Coulter,
and creatinine (Synchron Cx-7/Delta) was measured from
a morning spot urine sample. Albuminuria was evaluated
by urine albumin-to-creatinine ratio (UACR).

Follow-up at 7 Years
Trained outcomes assessors visited the homes of the participants 7 years after recruitment (2012–2014) to collect
follow-up data. Informed consent was obtained for participation in the study. BP was measured, and fasting blood
and urine samples were collected using the same protocol
as at baseline. BP change was calculated as follow-up BP
minus baseline BP. Participants were scheduled for an
echocardiogram at the central health facility.

Echocardiographic Data
The echocardiographic examination was carried out using the portable Philips CX50 imaging system by a trained
sonographer using standardized procedures and rigorous
quality assurance. All results were reviewed by a trained
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cardiologist. Left ventricular measurements were made using M-mode (MM) and two-dimensional (2D) echo from
the parasternal long axis, adhering to American Society
of Echocardiography guidelines.20 As in the LIFE Study,21
end-diastolic left ventricular septal and posterior wall thickness (PWT) and internal dimensions were used to calculate
LVM using the formula: LVM ¼ 1.04  0.8 ([left ventricular wall thicknesses þ internal dimension]  [internal
dimension]) þ 0.6 g. LVMI was calculated as LVM (based
on MM measurements) in grams divided by body surface
area in square meters. Two trained sonographers performed
all imaging for the study. Interrater reliability among
sonographers for LVMI was very good, with kappa ¼ 0.93.

Analysis
The primary outcome was LVMI, and the secondary
outcome was LVH defined as LVMI greater than 88 g/m2
in females and greater than 102 g/m2 in males.22
The ancillary outcomes of PWT at end diastole and
septal wall thickness (SWT) at end diastole were also
analyzed.
Besides baseline eGFR and baseline UACR, the main
exposure variables were (1) rate of decline in eGFR defined
as the difference between follow-up and baseline eGFR
divided by study duration in years and (2) rate of increase
in albuminuria defined as the difference between followup and baseline UACR divided by study duration in years.
A categorical variable was created using UACR tertile.

Statistical Analysis
Baseline characteristics together with rate of decline in
eGFR and increase in UACR as well as change in systolic
blood pressure (SBP) and diastolic blood pressure (DBP)
were summarized as mean and standard deviation or median and interquartile range for continuous variables and
as counts and percentage for categorical variables. Comparisons between groups with and without LVH were conducted using the 2-sample t-test for normally distributed
continuous variables and a chi-square test for categorical
variables. The Mann–Whitney U test was used to compare
groups for nonnormal continuous variables. The bivariate
correlations between SBP change and kidney biomarkers
were evaluated using Pearson correlation coefficient or
analysis of variance, where appropriate.
Associations between follow-up LVMI and the markers
eGFR and UACR unadjusted and adjusted for potential
confounders were investigated using linear regression analysis. Six models were developed by systematically selecting variables from a candidate set and introducing them
into the models:
 Model 1: Baseline eGFR; baseline UACR (model 1
for each variable)
 Model 2: Baseline eGFR þ baseline UACR
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 Model 3: Variables in model 2 þ age, gender, education, BMI, diabetes, heart disease, SBP, DBP, smoking, low-density lipoproteins (LDLs), high-density
lipoproteins, triglyceride, angiotensin-converting
enzyme inhibitor or angiotensin II receptor blocker
use, calcium channel blocker use, b-blocker use, diuretics use, and intervention group.
 Model 4: Variables in model 3 þ SBP change, DBP
change, and rate of decline in eGFR
 Model 5: Variables in model 3 þ SBP change, DBP
change, and rate of increase in UACR
 Model 6: Variables in model 3 þ SBP change, DBP
change, rate of increase in UACR, and rate of decline
in eGFR
Using the same model building approach, we performed
logistic regression to determine whether the two markers
were independently associated with follow-up LVH. In
addition, both PWT and SWT were analyzed in model 6.
We log-transformed UACR in all analyses given its rightskewed distribution. We explored interaction effects of kidney biomarkers with age, gender, SBP change, and DBP
change in multiple linear regression analysis. We also conducted a sensitivity analysis on model 6 by restricting the
analysis to individuals without heart disease. All analyses
accounted for clustering by household at the census level
as a random effect using the SAS GLIMMIX procedure.
Sensitivity analyses were performed using 2D measurements for LVMI. A two-sided P value of .05 was considered statistically significant. Statistical analyses were
performed using SAS, version 9.4 (SAS Institute, Inc,
Cary, NC).

Results
Study Population
Of all the original 1341 trial participants, 311 individuals
died, 198 migrated, and 92 were lost to follow-up, resulting
in 740 in the 7-year follow-up posttrial follow-up study. Of
the 740, 169 (22.8%) did not undergo echocardiograms for
either refusals or failure to keep appointment, and 571 had
echocardiographic data. From among the latter, we
excluded 26 (1.9%) with no baseline or follow-up serum
creatinine, urine albumin or urine creatinine, three missing
parameters for LVMI, three missing information on heart
disease, 10 missing LDL, high-density lipoprotein, and triglyceride, as well as one missing follow-up DBP, leaving
539 (40% of the original cohort and 73% of those at
7-year follow-up) individuals for analysis.
Compared to the excluded individuals from the original
cohort (n ¼ 802), those analyzed (n ¼ 539) were younger
and had higher education levels and lower rates of diabetes,
heart disease, and smoking. They also had higher baseline
BMI and eGFR, but lower baseline SBP and baseline
UACR (Table S1).
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The mean age among the 539 hypertensives included in the
analysis was 50.9  9.1 years, 63% were female and 34% had
no formal education (Table 1). Mean LVMI was 69.9  17.5 g/m2,
mean eGFR 91.0  15.9 mL/min/1.73 m2, and median
UACR (interquartile range) 6.2 (3.9, 11.3) mg/g.
Among men, participants with LVH had lower levels of
LDL, higher SBP change, and higher rate of UACR increase than those without LVH. Among women, participants with LVH were characterized by older age, higher
waist circumference, higher baseline SBP, lower baseline
eGFR, higher baseline UACR, higher SBP increase, and
higher rate of UACR increase than those without LVH
(Tables 1 and 2). There were significant bivariate associations of change in SBP over 7 years with baseline UACR
(r ¼ 0.12, P ¼ .005), rate of UACR increase
(F2,536 ¼ 3.46, P ¼ .032), and rate of eGFR decline
(r ¼ 0.12, P ¼ .007), each.

Left Ventricular Mass Index
Table 3 shows the association of baseline, rate of decline
in eGFR, and rate of increase in UACR with LVMI at
7 years. In the univariate model (model 1), each 1 mL/
min/1.73 m2 decrease in baseline eGFR was significantly
associated with a 0.21 g/m2 increase in LVMI, and per
unit increase in log-transformed UACR (about 2.7 times
greater in UACR) was predictive of 2.87 g/m2 higher
LVMI. These associations were attenuated but remained
statistically significant when both markers (baseline eGFR
and baseline UACR) were introduced together in model
2. With further adjustment for demographic variables and
other confounders in models 3, 4, and 5, statistical significance persisted only for baseline UACR. Rate of decline in
eGFR and increase in UACR were significantly associated
with LVMI in models 4 and 5. After adjustment for rate of

Table 1
Baseline characteristics by left ventricular hypertrophy (LVH) among the hypertensive participants (n ¼ 539)
Variables

Total

Male
No LVH
(n ¼ 185)

Age, mean (SD)
Education, n (%)
Formal
Not formal
Waist circumference (cm)
SBP (mm Hg, mean, SD)
DBP (mm Hg, mean, SD)
Antihypertensive use, n (%)
ARB or ACEI, n (%)
b-Blocker, n (%)
CCB, n (%)
Diuretics, n (%)
Diabetes, n (%)
Heart disease, n (%)
Smoking, n (%)
Never
Current or past
LDL (mg/dL, mean, SD)
HDL (mg/dL, mean, SD)
Triglyceride (mg/dL, mean, SD)
eGFR (mL/min/1.73 m2, mean,
SD)
UACR (mg/g, median, IQR)
Intervention group, n (%)
No intervention
GP only
HHE only
GP and HHE

50.9 (9.1)

51.2 (8.5)

LVH
(n ¼ 14)
53.4 (10.6)

358
181
93.1
149.1
92.9
205
71
119
51
12
129
64

(66.4)
(33.6)
(11.0)
(22.6)
(12.3)
(38.0)
(13.2)
(22.1)
(9.5)
(2.2)
(23.9)
(11.9)

161
24
96.1
149.4
93.4
62
24
39
13
3
32
21

(87.0)
(13.0)
(10.2)
(20.7)
(12.4)
(33.5)
(13.0)
(21.1)
(7.0)
(1.6)
(17.3)
(11.4)

12
2
92.7
142.9
89.6
2
0
2
1
0
5
2

(85.7)
(14.3)
(15.0)
(16.8)
(13.5)
(14.3)
(0.0)
(14.3)
(7.1)
(0.0)
(35.7)
(14.3)

333
206
120.4
40.3
179.4
91.0

(61.8)
(38.2)
(32.9)
(10.3)
(102.0)
(15.9)

82
103
118.1
36.3
192.8
86.4

(44.3)
(55.7)
(31.9)
(7.3)
(125.8)
(14.9)

3
11
100.2
39.0
191.5
75.4

(21.4)
(78.6)
(25.2)
(8.6)
(130.9)
(26.8)

6.2 (3.9, 11.3)

4.9 (3.1, 8.1)

137
107
129
166

49
40
44
52

(25.4)
(19.9)
(23.9)
(30.8)

(26.5)
(21.6)
(23.8)
(28.1)

Female
P Value
.37
1.00

.42
.25
.26
.23
.23
.74
1.00
1.00
.14
.67
.10

.042
.19
.68
.12

8.2 (3.7, 13.8) .18
.17
3 (21.4)
6 (42.9)
4 (28.6)
1 (7.1)

No LVH
(n ¼ 298)
49.9 (9.0)

LVH
(n ¼ 42)
56.8 (9.2)

163
135
91.0
147.8
92.7
119
39
64
33
7
80
38

(54.7)
(45.3)
(10.9)
(23.6)
(12.3)
(39.9)
(13.1)
(21.5)
(11.1)
(2.4)
(26.9)
(12.8)

22
20
94.6
158.8
92.9
22
8
14
4
2
12
3

(52.4)
(47.6)
(10.9)
(22.9)
(11.0)
(52.4)
(19.1)
(33.3)
(9.5)
(4.8)
(28.6)
(7.1)

218
80
122.0
42.7
168.8
95.5

(73.2)
(26.9)
(34.0)
(11.1)
(80.6)
(13.5)

30
12
126.3
41.6
191.9
84.3

(71.4)
(28.6)
(29.0)
(11.1)
(105.7)
(19.4)

6.6 (4.3, 11.8)

9.6 (6.1, 29.3)

77
53
71
97

8
8
10
16

(25.8)
(17.8)
(23.8)
(32.6)

P Value
<.001
.78

.043
.005
.89
.13
.29
.087
1.00
.31
.81
.30
.81

.44
.55
.42
<.001
.003
.79

(19.1)
(19.1)
(23.8)
(38.1)

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; DBP, diastolic
blood pressure; eGFR, estimated glomerular filtration rate; GP, general practitioner; HDL, high-density lipoprotein; HHE, home health education; IQR, interquartile range; LDL, low-density lipoprotein; SBP, systolic blood pressure; SD, standard deviation; UACR, urine albumin to creatinine ratio.
Mann–Whitney U test for UACR, LVH was defined as LVMI > 88 g/m2 for women, >102 g/m2 for man.

Variables

Total

Male

Female

No LVH (n ¼ 185) LVH (n ¼ 14)
SBP change (mm Hg)
Mean, SD
Median, IQR
DBP change (mm Hg)
Mean, SD
Median, IQR
Rate of decline in eGFR (mL/min/1.73 m2/y)y
Mean, SD
Median, IQR
Rate of increase in UACR (mg/g/y, median, IQR)z
Rate of increase in UACR (mg/g/y)
<0.14
0.14–1.07
1.07

0.1 (24.1)
2 (15.5, 15.5)

0.8 (21.1)
2.0 (11.0, 15.0)

P Value No LVH (n ¼ 298) LVH (n ¼ 42)

P Value

.032

.026
2.3 (24.9)
0 (17.5, 13.5)

13.8 (29.0)
8.8 (5.0, 32.0)

6.9 (26.9)
9.3 (6.0, 20.5)

.081
6.3 (14.2)
6.0 (14.0, 3.5)

5.7 (13.0)
5.0 (14.0, 3.5)

0.3 (1.8)
0.0 (0.8, 0.7)
0.5 (0.0, 1.6)

0.2 (1.3)
0.1 (0.6, 0.8)
0.3 (0.0, 1.5)

0.7 (14.8)
0.5 (15.0, 13.5)

.53
7.1 (14.7)
6.0 (15.0, 2.0)

5.6 (15.6)
4.0 (14.0, 7.0)

0.4 (1.9)
0.0 (1.3, 0.7)
0.5 (0.0, 1.5)

0.8 (2.4)
0 (2.7, 0.7)
1.2 (0.1, 4.1)

.15

179 (33.2)
178 (33.0)
182 (33.8)

71 (38.4)
55 (29.7)
59 (31.9)

0.3 (1.8)
0.1 (0.7, 1.4)
1.3 (0.4, 5.0)
2 (14.3)
5 (35.7)
7 (50.0)

.040
.16

.38

96 (32.2)
109 (36.6)
93 (31.2)

.045
.01

10 (23.8)
9 (21.4)
23 (54.8)

DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; IQR, interquartile range; LVMI, left ventricular mass index; SBP, systolic blood pressure; SD, standard
deviation; UACR, urine albumin-to-creatinine ratio.
Mann–Whitney U test for rate of increase in UACR, LVH was defined as LVMI > 88 g/m2 for women, >102 g/m2 for men.
* Change in blood pressure was calculated using blood pressure at year 7 minus baseline blood pressure.
y
Rate of decline in eGFR ¼ (eGFR at year 7  eGFR at baseline)/duration of follow up (in y).
z
Rate of increase in UACR ¼ (UACR at year 7  UACR at baseline)/duration of follow up (in y).
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Table 2
Change in blood pressure and renal function by left ventricular hypertrophy (LVH) among the hypertensive participants (n ¼ 539)*

815
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Table 3
Association of baseline and rate of increase in eGFR (mL/min/1.73 m2) and UACR (mg/g) with LVMI (g/m2) (n ¼ 539) from multiple regression analysis
Variables

Model 1

Baseline eGFR
Baseline UACR
Gender (female)
Waist circumference
Baseline SBP
SBP change*
Rate of decline in
eGFRy
Rate of increase in
UACRz
<0.14 (Ref)
0.14–1.07
1.07

P Value b-Coefficient
(95% CI)

0.21
<.001
(0.30, 0.12)
2.87
<.001
(1.55, 4.18)

Model 3

Model 4

P
b-Coefficient P
b-Coefficient
Value (95% CI)
Value (95% CI)

0.18
<.001 0.07
(0.28, 0.09)
(0.19, 0.05)
2.51
<.001 2.08
(1.20, 3.82)
(0.72, 3.45)
1.35
(5.03, 2.34)
0.16
(0.02, 0.30)
0.16
(0.06, 0.27)

.23
.003
.47
.027
.003

Model 5
P
b-Coefficient
Value (95% CI)

Model 6
P
b-Coefficient
Value (95% CI)

0.11
.06 0.08 (0.19, 0.04) .18 0.11
(0.23, 0.01)
2.00
.003 2.31 (0.92, 3.72)
.001 2.26
(0.68, 3.32)
1.02
.57 0.93 (4.49, 2.63) .61 1.23
(4.57, 2.54)
0.18
.009 0.18 (0.04, 0.31)
.01
0.18
(0.05, 0.32)
0.30
<.001 0.29 (0.18, 0.40) <.001 0.29
(0.18, 0.41)
<.001 0.24 (0.14, 0.34) <.001 0.25
0.26
(0.16, 0.35)
1.15
.010
1.05
(2.03, 0.28)
.03
1.00
2.56 (1.07, 6.19)
4.61 (1.18, 8.05)

.17
.009

P
Value

(0.23, 0.00)

.06

(0.87, 3.65)

.002

(4.78, 2.33)

.50

(0.04, 0.32)

.01

(0.18, 0.40)

<.001

(0.15, 0.35)

<.001

(1.94, 0.17)

1.00
2.65 (0.97, 6.27)
4.19 (0.75, 7.63)

.02
.04

.15
.02

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CI, confidence interval; DBP, diastolic blood pressure;
eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVMI, left ventricular mass index; SBP, systolic blood pressure;
UACR, urine albumin-to-creatinine ratio.
Model 1: Baseline eGFR, baseline UACR (model 1 for each variable).
Model 2: Baseline eGFR þ baseline UACR.
Model 3: Variables in model 2 þ age, gender, education, waist circumference, diabetes, heart disease, SBP, DBP, smoking, LDL, HDL, triglyceride, ACEI or ARB use, CCB use,
b-blocker use, diuretics use, and intervention group.
Model 4: Variables in model 3 þ SBP change, DBP change, and rate of decline in eGFR.
Model 5: Variables in model 3 þ SBP change, DBP change, and rate of increase in UACR.
Model 6: Variables in model 3 þ SBP change, DBP change, rate of increase in UACR, and rate of decline in eGFR.
All models accounted for clustering effect by household as a random effect.
In addition to kidney function biomarkers and gender, variables with P value < .05 in model 6 were reported in the table.
* Change in SBP was calculated using SBP at year 7 minus baseline SBP.
y
Rate of decline in eGFR ¼ (eGFR at year 7  eGFR at baseline)/duration of follow-up (in y).
z
Rate of increase in UACR ¼ (UACR at year 7  UACR at baseline)/duration of follow-up (in y).
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b-Coefficient
(95% CI)

Model 2

Variables

Model 1
OR (95% CI)

Model 2
P Value OR (95% CI)

Baseline eGFR 0.97 (0.95, 0.98) <.001
Baseline UACR 1.44 (1.17, 1.76) <.001
Gender (female)
Baseline SBP
SBP change*
Rate of decline
in eGFRy
Rate of increase
in UACRz
<0.14
0.14–1.07
1.07

Model 3
P Value OR (95% CI)

0.97 (0.96, 0.99) <.001
1.32 (1.06, 1.63) .01

0.97
1.28
3.09
1.01

(0.95, 0.99)
(1.01, 1.63)
(1.34, 7.14)
(0.99-1.04)

Model 4

Model 5

Model 6

P Value OR (95% CI)

P Value OR (95% CI)

P Value OR (95% CI)

P Value

.01
.04
.008
.18

.004
.04
.006
.006
.001
.10

.01
.02
.006
.01
.004

.006
.03
.008
.01
.003
.19

0.97
1.30
3.43
1.03
1.03
0.87

(0.95,
(1.01,
(1.42,
(1.01,
(1.01,
(0.73,

0.99)
1.67)
8.31)
1.06)
1.05)
1.02)

0.97
1.39
3.45
1.03
1.03

(0.95,
(1.05,
(1.43,
(1.01,
(1.01,

0.99)
1.83)
8.32)
1.06)
1.05)

0.97
1.37
3.29
1.03
1.03
0.89

(0.95,
(1.04,
(1.36,
(1.01,
(1.01,
(0.75,

0.99)
1.80)
7.96)
1.06)
1.05)
1.06)

.11

.17

1.00
1.65 (0.64, 4.25) .30
2.33 (1.06, 5.14) .04

1.00
1.64 (0.64, 4.23) .31
2.17 (0.97, 4.83) .06

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CI, confidence interval; DBP, diastolic blood pressure;
eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVH, left ventricular hypertrophy; OR, odds ratio; SBP, systolic blood
pressure; UACR, urine albumin-to-creatinine ratio.
Model 1: Baseline eGFR; baseline UACR (model 1 for each variable).
Model 2: Baseline eGFR þ baseline UACR.
Model 3: Variables in model 2 þ age, gender, education, waist circumference, diabetes, heart disease, SBP, DBP, smoking, LDL, HDL, triglyceride, ACEI or ARB use, CCB use,
b-blocker use, diuretics use, and intervention group.
Model 4: Variables in model 3 þ SBP change, DBP change, and rate of decline in eGFR.
Model 5: Variables in model 3 þ SBP change, DBP change, and rate of increase in UACR.
Model 6: Variables in model 3 þ SBP change, DBP change, rate of increase in UACR, and rate of decline in eGFR.
All models accounted for clustering effect by household as a random effect.
In addition to kidney function biomarkers, variables with P value < .05 in model 6 were reported.
* Change in SBP was calculated using SBP at year 7 minus baseline SBP.
y
Rate of decline in eGFR ¼ (eGFR at year 7  eGFR at baseline)/duration of follow-up (in y).
z
Rate of increase in UACR ¼ (UACR at year 7  UACR at baseline)/duration of follow-up (in y).
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Table 4
Association of baseline and rate of increase in eGFR (mL/min/1.73 m2) and UACR (mg/g) with LVH from logistic regression analysis (n ¼ 539)
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Table 5
Association of baseline and rate of increase in eGFR (mL/min/1.73 m2) and UACR (mg/g) with posterior wall thickness (cm) and septal
wall thickness (cm) (n ¼ 539) from multiple regression analysis
Variables

Posterior Wall Thickness (M Mode)
b Coefficient (95% CI)

Baseline eGFR
Baseline UACR
Rate of decline in eGFR*
Rate of increase in UACRy
<0.14 (Ref)
0.14–1.07
1.07
Gender (female)
Waist circumference
Baseline SBP
SBP changez

0.0001 (0.0007, 0.0008)
0.0114 (0.0025, 0.0203)
0.0075 (0.0132, 0.0019)

0.0260
0.0232
0.0320
0.0024
0.0014
0.0007

(0.0028, 0.0492)
(0.0011,0.0452)
(0.0548, 0.0092)
(0.0015, 0.0032)
(0.0006, 0.0021)
(0.0001, 0.0013)

Septal Wall Thickness (M Mode)
P Value
.83
.013
.009
.048
.028
.039
.006
<.001
<.001
.022

b Coefficient (95% CI)
0.0003 (0.0005, 0.0012)
0.0120 (0.0021, 0.0219)
0.0010 (0.0072, 0.0053)

0.0285
0.0329
0.0362
0.0022
0.0015
0.0006

(0.0028, 0.0542)
(0.0085, 0.0573)
(0.0614, 0.0109)
(0.0013, 0.0032)
(0.0007, 0.0023)
(0.0001, 0.0013)

P Value
.44
.018
.76
.019
.03
.008
.005
<.001
<.001
.098

ARB, angiotensin II receptor blocker; ACEI, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker; DBP, diastolic
blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic
blood pressure; UACR, urine albumin-to-creatinine ratio.
Note: Variables in the model were baseline eGFR, baseline UACR, rate of decline in eGFR, rate of increase in UACR, age, gender,
education, waist circumference, diabetes, heart disease, SBP, SBP change, DBP, DBP change, smoking, LDL, HDL, triglyceride, ACEI
or ARB use, CCB use, b-blocker use, diuretics use, and intervention group.
All models accounted for clustering effect by household as a random effect.
In addition to kidney function biomarkers, variables with P value < .05 for either outcomes were reported in the table.
* Rate of decline in eGFR ¼ (eGFR at year 7  eGFR at baseline)/duration of follow-up (in y).
y
Rate of increase in UACR ¼ (UACR at year 7  UACR at baseline)/duration of follow-up (in y).
z
Change in SBP was calculated using SBP at year 7 minus baseline SBP.

decline in eGFR and increase in UACR in model 6, the significant association between baseline UACR and LVMI
persisted. In addition, every 1 mL/min/1.73 m2/y decline
in eGFR was significantly associated with 1.05 g/m2 higher
LVMI at the end of follow-up (P ¼ .02). LVMI significantly
increased by 4.19 g/m2 in those with rate of UACR increase
of 1.07 mg/g/y compared to individuals with UACR rate
of increase of <0.14 mg/g/y (P ¼ .02), and although not
statistically significant, by 2.65 g/m2 in those with rate of
UACR increase of between 0.14 and 1.07 mg/g/y
(P ¼ .15). Other covariates positively associated with
LVMI were waist circumference (b ¼ 0.18; 95% confidence interval [CI]: [0.04, 0.32]), SBP (b ¼ 0.29; 95%
CI: [0.18, 0.40]), and SBP change (b ¼ 0.25; 95% CI:
[0.15, 0.35]). No significant interactions were observed between age, gender, change in SBP, or change in DBP with
kidney biomarkers on LVMI. Analysis results remained unchanged after excluding individuals with heart disease at
baseline (Table S2).
Sensitivity analysis using 2D-mode measurement of
LVMI yielded consistent results.

Left Ventricular Hypertrophy
The adjusted associations between kidney biomarkers
and LVH are summarized in Table 4. In the final model

(model 6), both baseline eGFR and baseline UACR were
significantly associated with LVH (eGFR: odds ratio
[OR] ¼ 0.97; 95% CI: [0.95, 0.99]; UACR: OR ¼ 1.37;
95% CI: [1.04, 1.80]). Rate of UACR increase group of
1.07 mg/g/y conferred a 2.17-time greater risk of LVH
(OR ¼ 2.17; 95% CI: [0.97–4.83]) using <0.14 mg/g/y
as the reference group. In contrast, there was no association
between rate of eGFR decline and LVH, albeit the direction
of association was similar to that of LVMI.

PWT and SWT
Table 5 shows the multivariate association of kidney
biomarkers with the outcomes of PWT and SWT. Higher
baseline UACR and greater rate of eGFR decline were
significantly associated with increase in PWT. Rate of
UACR increase between groups of 0.14 and 1.07 mg/g/y
and 1.07 mg/g/y both was associated with higher PWT
as compared with group of rate <0.14 mg/g/y. However,
baseline eGFR had no association with PWT. As for
SWT, both baseline UACR and rate of increase in
UACR were positively associated with SWT. In contrast,
no association was identified between baseline eGFR or
its rate of decline and SWT. Sensitivity analysis using
2D-mode measurements of PWT and SWT yielded consistent results.
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Discussion
Our study examining the association of markers of kidney
function and damage with LVMI among 539 hypertensive
individuals with near normal kidney function from the general population in communities in Pakistan found that higher
baseline UACR, greater rate of increase in UACR, and
greater rate of decline in eGFR were strongly and independently associated with higher LVMI at the 7-year follow-up.
Similar results were found for PWT and SWT, except that
rate of eGFR decline was not associated SWT. Higher baseline UACR, lower baseline eGFR, and the rate of increase in
UACR of 1.07 mg/g/y versus <0.14 mg/g/y predicted
greater risk of LVH. Our findings based on the first study
of its kind in communities in South Asia have tremendous
clinical and public health implications for screening and
monitoring kidney markers, each offering prognostic information for risk stratification of individuals at high risk of
adverse cardiac outcomes, especially in South Asians—a
population known to be at high risk of CVD.15,16
Our findings corroborate studies in other populations9–13
indicating that kidney dysfunction as a static measure or evidence of progressive worsening over time predicted higher
LVMI. Presence of albuminuria has been shown to predict
future LVMI in individuals with hypertension.23,24 A reduction in microalbuminuria has been shown to be a significant
predictor of reduced chance of LVH regression.12 In addition, in a report by Bansal et al,11 decline in eGFR was
significantly associated with higher LVMI 10 years later
in a sample of 2410 black and white participants with baseline eGFR >60 mL/min/1.73 m2. Furthermore, parallel
worsening of eGFR and albuminuria, compared to either
alone, has been associated with greater LVMI.24 Our study
extends previous research by evaluating dynamic change in
UACR and eGFR in combination for prediction of cardiac
abnormalities and to demonstrate independent long-term
effects of markers of both static and dynamic kidney damage parameters on LVMI in hypertensive individuals in
low-income communities in South Asia.
It is important to highlight that in our study, change in
SBP was significantly correlated with baseline UACR,
rate of UACR increase, rate of eGFR decline, and LVMI.
However, the associations between markers of kidney damage with LVMI were independent of baseline SBP and its
change over the follow-up. Few studies adjusted for change
in SBP when examining the effect of kidney dysfunction on
cardiac structure.11,13
It is also interesting to note that decline in eGFR was
associated with increase in PWT; however, its relationship
with SWT was not significant. This suggests the possibility
of eccentric left ventricular hypertrophy being associated
with reduced kidney function which has been reported
previously.25
The mechanisms linking kidney dysfunction to cardiac
abnormalities are still unclear. Traditional cardiovascular
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risk factors at baseline such as hypertension, diabetes,
high cholesterol, and smoking do not entirely explain the
associations because they were controlled for in the analysis. Likewise, the multivariable analysis was adjusted for
greater decline in systolic BP among those without LVH
compared to those with LVH. In patients with chronic kidney disease, anemia is a potential factor mediating the association between markers of kidney dysfunction and
LVMI. Average eGFR was high in our population
(91 mL/min/1.73 m2) with only two subjects having an
eGFR of <30 mL/min/1.73 m2. Therefore, we believe
that low hemoglobin may not play a major role in the
observed associations. Albuminuria is theoretically related
to multiple pathophysiological processes including comorbidities, systemic inflammation, and endothelial dysfunction and is a marker of generalized cardiovascular
damage.26,27 Other possible factors could be overactivity
of the renin–aldosterone system and sympathetic tone and
alteration in mineral metabolism such as 1,25hydroxyvitamin D, parathyroid hormone, and fibroblast
growth factor 23,28–30 all of which are associated with progressive kidney dysfunction and contribute to the development and worsening of cardiac damage.
There are limitations in the study. First, echocardiography was not performed at baseline, and we were not able
to evaluate possible confounding by baseline LVMI. However, we accounted for the presence of known heart disease
in the main analysis. Further, sensitivity analysis after
exclusion of individuals with heart disease yielded consistent results. Nevertheless, residual confounding by subclinical structural change could not be controlled for
adequately. For this reason, it is not possible to establish
a cause-effect relationship in this study. However, our findings do establish the predictive association of eGFR and
UACR with LVMI and LVH. Second, 40% of the original
COBRA cohort were available with echocardiographic
data for analysis at 7-year follow-up. The analytic sample
represents relatively healthier hypertensive individuals
with better kidney function and lower prevalence of heart
disease and diabetes than the general population in the urban communities of Pakistan. Consequently, we expect
higher associations would be found in individuals with
more adverse risk factor profile. However, studies elsewhere have reported potential utility of eGFR and UACR
to the Framingham risk score as prognostic of CVD mortality in patients with advanced kidney disease.31 Thus, our
findings might be generalizable to most of the general population in the communities in South Asia and possibly
neighboring countries, but additional studies are required
in more representative samples of hypertensive individuals
with a wide spectrum risk profile. Third, history of hypertension and legacy effect of uncontrolled BP were not accounted for in the analysis. However, use of
antihypertensive medications is known to lead to LVH
regression.32 Fourth, we only measured kidney biomarkers
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at baseline and end of follow-up and thus can only examined the linear changes in kidney biomarkers over time.
Finally, LVMI measurements using MM and 2D echocardiographic imaging have limitations including operatordependent technical issues such as image quality and
beam positioning as well as the assumption of a uniform
geometric shape of the left ventricle. However, the sonographers performing imaging in our study were trained as
per ASE guidelines with good interrater reproducibility
measures.33
The main strengths of our study include a communitybased sample identified using door-to-door census in
South Asia and rigorous measurement procedures
enhancing generalizability of findings to public health settings. Other major strengths include long follow-up duration, improved accuracy of glomerular filtration rate
estimate using a locally modified CKD-EPI creatinine
equation and IDMS calibrated serum creatinine, adjustment for important confounders rarely considered in early
studies (eg, BP change and lipid profile), and high quality
echocardiographic imaging with sound reliability measurements. In addition, results of sensitivity analysis using
2D imaging were consistent with MM, as were ancillary
analyses for association of all kidney biomarkers with
PWT and UACR with SWT. Thus, we believe our findings
are robust.
Our findings have tremendous implications for public
health and clinical practice especially in South Asian countries where CVD is the leading cause of mortality accounting for one-third of all deaths with tremendous economic
consequences.15
Point of care testing for kidney function is available
across a variety of primary care settings, including care
by trained health workers providing home health checks
and education in resource-constrained regions globally.34
The PREVEND Study in the Netherlands demonstrated
that lowering albuminuria can prevent heart failure.35 Our
results suggest that screening for both eGFR and UACR
at baseline and during follow-up should be evaluated for
risk stratification and subsequent prevention of future
LVH and CVD in South Asians with hypertension. Such
an approach is likely to be cost-effective especially in
resource-constrained settings where access to cardiac imaging technologies is limited.
In conclusion, higher baseline albuminuria, lower baseline eGFR, and their longitudinal worsening over 7 years
were significantly associated with higher LVMI or the
development of LVH among individuals with hypertension
in Pakistan. The findings suggest that both baseline
screening and follow-up monitoring eGFR and UACR
could potentially enhance cardiovascular risk stratification
for cardiac structural damage and subsequent CVD. Future
studies should consider both static and dynamic marker of
kidney dysfunction for risk stratification and prevention of
CVD.
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Table S1
Comparison of baseline characteristics between individuals in analytic sample and those excluded from the analysis
Variable
Age, mean (SD)
Female, n (%)
Education, n (%)
Formal
Not formal
BMI (kg/m2, mean, SD)
SBP (mm Hg, mean, SD)
DBP (mm Hg, mean, SD)
ARB or ACEI, n (%)
b-Blocker, n (%)
CCB, n (%)
Diuretics, n (%)
Diabetes, n (%)
Heart disease, n (%)
Smoking, n (%)
Never
Current or past
LDL (mg/dL, mean, SD)
HDL (mg/dL, mean, SD)
Triglyceride (mg/dL, mean, SD)
eGFR (mL/min/1.73 m2, mean, SD)
UACR (mg/g, median, IQR)
Intervention group, n (%)
No intervention
GP only
HHE only
GP and HHE

n

Analytic Sample (n ¼ 539)
50.9 (9.06)
340 (63.1)

Excluded (n ¼ 802)
55.9 (12.2)
500 (62.3)

1279
1334

358
181
27.7
149.1
92.9
71
119
51
12
129
64

(66.2)
(33.6)
(5.0)
(22.6)
(12.3)
(13.2)
(22.1)
(9.5)
(2.2)
(23.9)
(11.9)

429
373
26.0
153.2
93.1
112
153
78
27
241
119

(53.5)
(46.5)
(5.5)
(25.6)
(13.6)
(14.0)
(19.1)
(9.7)
(3.4)
(32.6)
(14.8)

1271
1271
1271
1271
1272

333
206
120.4
40.3
179.4
91.0
6.2

(61.8)
(38.2)
(32.9)
(10.3)
(102)
(15.9)
(3.9, 11.3)

401
401
118.9
40.9
165
84.2
6.9

(50.0)
(50.0)
(32.4)
(10.7)
(84.1)
(20.9)
(4.4, 19.7)

1337

137
107
129
166

(25.4)
(19.9)
(23.9)
(30.8)

189
228
219
166

P Value
<.001
.78
<.001
<.001
.002
.78
.68
.18
.87
.22
<.001
.11
<.001

.40
.31
.007
<.001
<.001
<.001

(23.6)
(28.4)
(27.3)
(20.7)

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CCB, calcium channel
blocker; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; GP, general practitioner; HDL, high-density lipoprotein;
HHE, home health education; IQR, interquartile range; LDL, low-density lipoprotein; SBP, systolic blood pressure; SD, standard deviation;
UACR, urine albumin-to-creatinine ratio.

822.e2

L. Feng et al. / Journal of the American Society of Hypertension 11(12) (2017) 811–822

Table S2
Association of baseline and rate of increase in eGFR (mL/min/
1.73 m2) and UACR (mg/g) with LVMI (g/m2) in individuals
without heart disease (n ¼ 475) from multiple regression
Variables

Baseline eGFR
Baseline UACR
Gender (female)
BMI
Baseline SBP
SBP change*
Rate of increase in eGFRy
Rate of increase in UACRz
<0.14
0.14–1.07
1.07

Without Heart Disease N ¼ 475
b-Coefficient 95% (CI)

P Value

0.12
2.29
1.96
0.31
0.30
0.26
1.04

.06
.003
.33
.06
<.001
<.001
.03
.05

(0.24, 0.01)
(0.80, 3.77)
(5.90, 1.98)
(0.02, 0.65)
(0.18, 0.42)
(0.16, 0.36)
(2.00, 0.09)

Reference
2.86 (1.05, 6.77)
4.60 (0.87, 8.33)

.15
.02

BMI, body mass index; CI, confidence interval; eGFR, estimated
glomerular filtration rate; LVMI, left ventricular mass index; SBP,
systolic blood pressure; UACR, urine albumin-to-creatinine ratio.
Analysis was based on model 6 including all covariates and accounted for clustering effect by household as a random effect.
* Change in SBP was calculated using SBP at year 7 minus
baseline SBP.
y
Rate of increase in eGFR ¼ (eGFR at year 7  eGFR at baseline)/duration of follow-up (in y).
z
Rate of increase in UACR ¼ (UACR at year 7  UACR at
baseline)/duration of follow-up (in y).

